Michael Ian Mackness

Michael Ian Mackness's AcademicInfluence.com Rankings

Philosophy

#11501

Historical Rank

Logic

#6583

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Michael Ian Mackness's Degrees

PhD Medical Sciences University of Oxford

Why Is Michael Ian Mackness Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael Ian Mackness's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial (2004) (3586)
Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein (1991) (977)
Paraoxonase and Atherosclerosis (2001) (837)
Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. (1993) (823)
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. (1991) (542)
Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins (1996) (490)
Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype? (2001) (483)
Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective Study (2003) (437)
Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. (1995) (423)
Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India (1995) (400)
Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification (1998) (389)
Human serum paraoxonase. (1998) (355)
HDL, its enzymes and its potential to influence lipid peroxidation (1995) (340)
The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. (1993) (330)
Serum paraoxonase after myocardial infarction. (1999) (322)
Systemic Lupus Erythematosus: An Independent Risk Factor for Endothelial Dysfunction in Women (2004) (294)
Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. (2001) (292)
Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. (1998) (281)
Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. (2006) (270)
An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia (2001) (259)
Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. (1986) (247)
Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles. (2015) (234)
Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon (1997) (220)
Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. (1997) (217)
How high-density lipoprotein protects against the effects of lipid peroxidation (2000) (207)
Paraoxonase and coronary heart disease. (2002) (205)
Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation (1997) (185)
Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein Antioxidant Defense Are Associated With Increased Macrophage Homing and Atherosclerosis in Dyslipidemic Obese Mice: LCAT Gene Transfer Decreases Atherosclerosis (2003) (179)
Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. (2004) (177)
Paraoxonase and coronary heart disease. (1998) (174)
Human Paraoxonase-1 Overexpression Inhibits Atherosclerosis in a Mouse Model of Metabolic Syndrome (2006) (172)
Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? (2004) (166)
Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. (2008) (164)
Hydrolysis of platelet-activating factor by human serum paraoxonase. (2001) (157)
Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. (1998) (152)
The Role of Paraoxonase 1 Activity in Cardiovascular Disease (2004) (145)
Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. (2000) (140)
Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. (1994) (135)
Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls (2002) (135)
Weight Loss-Associated Induction of Peroxisome Proliferator-Activated Receptor-&agr; and Peroxisome Proliferator–Activated Receptor-&ggr; Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice (2004) (131)
HDL, its enzymes and its potential to influence lipid peroxidation. (1995) (131)
Esterases: problems of identification and classification. (1983) (128)
Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip (2002) (126)
The paraoxonase gene family and coronary heart disease (2002) (118)
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia (2000) (117)
Paraoxonase 1 activity, concentration and genotype in cardiovascular disease (2004) (116)
Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease (2009) (114)
Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides (2008) (111)
Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. (1991) (104)
Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. (1993) (94)
Non-enzymatic glycation of apolipoprotein B in the sera of diabetic and non-diabetic subjects. (1992) (94)
Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. (2006) (93)
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes (2002) (93)
The separation of sheep and human serum "A"-esterase activity into the lipoprotein fraction by ultracentrifugation. (1985) (90)
Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. (2003) (89)
Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. (2000) (88)
Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. (2010) (87)
Human tissue distribution of paraoxonases 1 and 2 mRNA (2010) (86)
'A'-esterases. Enzymes looking for a role? (1989) (85)
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. (2003) (83)
Paraoxonase and susceptibility to organophosphorus poisoning in farmers dipping sheep. (2003) (83)
Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation (1999) (81)
Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. (2000) (80)
Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. (2007) (75)
Increased transfer of cholesteryl esters from high density lipoproteins to low density and very low density lipoproteins in patients with angiographic evidence of coronary artery disease. (1993) (74)
Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia. (1994) (73)
The correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with coronary heart disease status. (2006) (69)
Serum esterase activities and hyperlipidaemia in the streptozotocin-diabetic rat. (1990) (67)
Is paraoxonase related to atherosclerosis. (1993) (67)
An investigation of the role of lecithin:cholesterol acyltransferase and triglyceride-rich lipoproteins in the metabolism of pre-beta high density lipoproteins. (1991) (66)
Low A-esterase activity in serum of patients with fish-eye disease. (1987) (64)
Effect of organophosphate intoxication on human serum paraoxonase (2002) (63)
Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. (2007) (60)
Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure (2003) (60)
Distinction between 'A'-esterases and arylesterases. Implications for esterase classification. (1987) (60)
High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. (2006) (59)
The hunt for nutritional and pharmacological modulators of paraoxonase. (2002) (59)
Defective Metabolism of Oxidized Phospholipid by HDL From People With Type 2 Diabetes (2006) (57)
Book - The Paraoxonases: Their role in disease development and xenobiotic metabolism (2008) (56)
Abnormalities of VLDL, IDL, and LDL characterize insulin-dependent diabetes mellitus. (1992) (55)
Immunohistochemical analysis of paraoxonases‐1 and 3 in human atheromatous plaques (2011) (55)
Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation (2012) (54)
Lack of protection against oxidative modification of LDL by avian HDL. (1998) (53)
Paraoxonase-1 deficiency is associated with severe liver steatosis in mice fed a high-fat high-cholesterol diet: a metabolomic approach. (2013) (53)
Hypoxia induces HSP 70 gene expression in human hepatoma (HEP G2) cells. (1995) (52)
Impaired paraoxonase-1 status in obese children. Relationships with insulin resistance and metabolic syndrome. (2013) (52)
Tissue distribution and expression of paraoxonases and chemokines in mouse: the ubiquitous and joint localisation suggest a systemic and coordinated role (2010) (52)
Fetal and maternal lipoprotein metabolism in human pregnancy complicated by type I diabetes mellitus. (1998) (50)
Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins. (1992) (50)
Paraoxonase 1 gene transfer lowers vascular oxidative stress and improves vasomotor function in apolipoprotein E‐deficient mice with pre‐existing atherosclerosis (2008) (49)
Vitamin E supplementation increases the resistance of both LDL and HDL to oxidation and increases cholesteryl ester transfer activity. (2000) (49)
The effects of low‐dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women (1998) (48)
Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. (1997) (48)
Paraoxonase in Persian Gulf War Veterans (2003) (47)
Targeting paraoxonase-1 in atherosclerosis (2013) (47)
Absence of "A"-esterase activity in the serum of a patient with Tangier disease. (1989) (45)
The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein. (2003) (45)
Comparison of the ability of paraoxonases 1 and 3 to attenuate the in vitro oxidation of low-density lipoprotein and reduce macrophage oxidative stress. (2008) (45)
Multiple forms of sheep serum A-esterase activity associated with the high-density lipoprotein. (1988) (45)
Low serum paraoxonase: a risk factor for atherosclerotic disease? (1999) (44)
Paraoxonase 1 status in the Thai population (2005) (44)
The effects of fatty acids on apolipoprotein B secretion by human hepatoma cells (HEP G2). (2000) (42)
Partial purification and properties of sheep serum "A'-esterases. (1983) (40)
Oxygen regulation of TGF-beta 1 mRNA in human hepatoma (Hep G2) cells. (1994) (40)
The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. (1993) (40)
The paraoxonase‐2‐310 polymorphism is associated with the presence of microvascular complications in diabetes mellitus (2005) (39)
Effect of Treatment With a Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor on Fasting and Postprandial Plasma Lipoproteins and Cholesteryl Ester Transfer Activity in Patients with NIDDM (1995) (39)
Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment (2010) (38)
Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. (2008) (36)
Serum lipoprotein (a) in renal transplant recipients receiving cyclosporin monotherapy. (1993) (35)
Influence of early diabetic nephropathy on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition. (1991) (35)
Esterase activity in homogenates of three strains of the rust red flour beetle Tribolium castaneum (Herbst) (1983) (35)
Endothelial dysfunction in Type 1 diabetes mellitus: relationship with LDL oxidation and the effects of vitamin E (1999) (34)
Paraoxonase-1 Inhibits Oxidized Low-Density Lipoprotein-Induced Metabolic Alterations and Apoptosis in Endothelial Cells: A Nondirected Metabolomic Study (2013) (34)
A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with type 1 (insulin-dependent) diabetes mellitus. (1992) (34)
The epigenetic regulation of paraoxonase 1 (PON1) as an important enzyme in HDL function: The missing link between environmental and genetic regulation. (2019) (32)
The antioxidant properties of high-density lipoproteins in atherosclerosis. (2012) (32)
“A” esterases and their role in regulating the toxicity of organophosphates (2004) (31)
Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease (2013) (29)
Why plasma should not be used to study paraoxonase. (1998) (29)
Susceptibility of low‐ and high‐density lipoproteins from diabetic subjects to in vitro oxidative modification (1999) (29)
Transcriptional regulation of human Paraoxonase 1 by nuclear receptors. (2017) (28)
ADMINISTRATION OF EXOGENOUS ERYTHROPOIETIN β AFFECTS LIPID PEROXIDATION AND SERUM PARAOXONASE‐1 ACTIVITY AND CONCENTRATION IN PREDIALYSIS PATIENTS WITH CHRONIC RENAL DISEASE AND ANAEMIA (2007) (27)
Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy (2004) (26)
Serum paraoxonase-3 concentration is associated with insulin sensitivity in peripheral artery disease and with inflammation in coronary artery disease. (2012) (26)
No influence of increased intake of orange and blackcurrant juices and dietary amounts of vitamin E on paraoxonase-1 activity in patients with peripheral arterial disease (2007) (25)
Paraoxonase: another factor in NIDDM cardiovascular disease (1995) (25)
Lipoprotein secretion by the human hepatoma cell line Hep G2: differential rates of accumulation of apolipoprotein B and lipoprotein lipids in tissue culture media in response to albumin, glucose and oleate. (1991) (25)
The effect of night vision goggles on the retinocortical bioelectrical activity and its improvement by food supplement. (2012) (24)
Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. (1995) (24)
Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. (2010) (23)
Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes (2004) (23)
Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis. (1993) (23)
Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study[S] (2011) (23)
Paraoxonase-1 and clopidogrel efficacy (2011) (22)
Species differences in avian serum B esterases revealed by chromatofocusing and possible relationships of esterase activity to pesticide toxicity. (1991) (22)
Monocyte chemoattractant protein-1 and paraoxonase-1 and 3 levels in patients with sepsis treated in an intensive care unit: a preliminary report (2012) (21)
Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. (1994) (21)
Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations. (2010) (20)
'A'-esterase activity in the lipoprotein fraction of sheep serum. (1981) (20)
Severe insulin resistance, diabetes mellitus, hypertriglyceridemia, and pseudoacromegaly. (1996) (20)
Paraoxonase-1 status in patients with hereditary hemochromatosis (2013) (20)
Measurement of plasma small-dense LDL concentration by a simplified ultracentrifugation procedure and immunoassay of apolipoprotein B. (2003) (20)
Spontaneous platelet aggregation in whole blood is increased in non-insulin-dependent diabetes mellitus and in female but not male patients with primary dyslipidemia. (1995) (19)
Substrate specificity of human serum paraoxonase. (1991) (18)
Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation[S] (2012) (18)
Nonesterified fatty acids as mediators of glucose intolerance in Indian Asian populations. (2005) (17)
Clinical, biochemical, and immunohistochemical features of necrobiotic xanthogranulomatosis (2003) (17)
Paraoxonase-1 Is Not Associated with Coronary Artery Calcification in Type 2 Diabetes: Results from the PREDICT Study (2012) (17)
Human serum paraoxonase is inhibited in EDTA plasma. (1998) (16)
Comprar The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism | Mackness, Bharti | 9781402065606 | Springer (2008) (16)
Comparison of paraoxonase 1 measurements in serum and in lithium-heparin-anticoagulated plasma samples. (2005) (16)
Paraoxonase-1 is associated with corneal endothelial cell alterations in patients with chronic obstructive pulmonary disease. (2013) (16)
Current Aspects of Paraoxonase-1 Research (2014) (16)
The role of combined assessment of defense against oxidative stress and inflammation in the evaluation of peripheral arterial disease. (2011) (16)
The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia. (1992) (16)
Serum paraoxonase-3 concentration is associated with the severity of hepatic impairment in patients with chronic liver disease. (2011) (16)
High-density lipoprotein: why all the fuss? (2009) (15)
Peroxisomal localization of glucose-6-phosphate dehydrogenase and pyrophosphate-stimulated dihydroxyacetone-phosphate acyltransferase in mouse kidney. (1987) (15)
PON1 concentration and high-density lipoprotein characteristics as cardiovascular biomarkers (2019) (15)
PON1 lactonase activity and its association with cardiovascular disease. (2019) (14)
Treatment of mixed hyperlipidaemia using a combination of omega-3 fatty acids and HMG CoA reductase inhibitor (2001) (14)
The effect of atorvastatin on serum lipoproteins in acromegaly (2005) (14)
Lipid external quality assessment: commutability between external quality assessment and clinical specimens (2008) (13)
GST, CYP and PON1 polymorphisms in farmers attributing ill health to organophosphate-containing sheep dip (2007) (13)
A prospective study of serum lipoproteins after coronary artery bypass surgery. (1994) (13)
Paraoxonase polymorphisms and coronary heart disease (2004) (13)
Toxicity of pesticides to birds; the enzymic factor. (1991) (12)
‘Dippers' flu’ and its relationship to PON1 polymorphisms (2010) (12)
Paraoxonase polymorphisms and self-reported chronic ill-health in farmers dipping sheep. (2005) (12)
Esterases, lipases, and phospholipases : from structure to clinical significance (1994) (12)
Subcellular localization of epoxide hydrolase in mouse liver and kidney. (1986) (12)
A ‘Fish‐eye disease’ familial condition with massive corneal opacities and hypoalphalipoproteinaemia: clinical, biochemical and genetic features (1991) (12)
Paraoxonase gene polymorphism and serum activity in progressive IgA nephropathy. (2006) (11)
Serum paraoxonase-1 activity and genetic polymorphisms: common errors in measurement and interpretation of results (2010) (11)
Phenotypes and concentration of PON1 in cardiovascular disease: The role of nutrient intake. (2019) (10)
Esterases, Lipases, and Phospholipases (1994) (10)
Paraoxonase-1 and -3 Protein Expression in the Brain of the Tg2576 Mouse Model of Alzheimer’s Disease (2020) (8)
The Human Serum Paraoxonase Polymorphism and Atherosclerosis (1994) (8)
Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis (2022) (8)
Epigenetics of paraoxonases. (2020) (8)
‘A’-esterase activity in the lipoprotein fraction of sheep and human serum (1985) (7)
Purification and immunological characterization of pigeon serum butyrylcholinesterase. Implications on environmental monitoring and toxicological testing of birds. (1993) (7)
Influence of PON1 polymorphisms on the association between serum paraoxonase 1 and homocysteinemia in a general population. (2006) (7)
The Role of Paraoxonase in Lipid Metabolism (2002) (7)
Cholesteryl‐ester transfer protein enhances the ability of high‐density lipoprotein to inhibit low‐density lipoprotein oxidation (2011) (7)
Effect of dilution on high-density lipoprotein associated paraoxonase-1 activity. (2011) (6)
Paraoxonase 1: biochemistry and contribution to atherosclerosis (2004) (6)
Effects of insulin and glucagon on the secretion of apolipoprotein B-containing lipoproteins and triacylglycerol synthesis by human hepatoma (Hep G2) cells (1994) (5)
Defective metabolism of oxidised-phospholipid by high-density lipoprotein from people with type 2 diabetes (2006) (5)
Nonenzymatic glycation of apolipoprotein B in diabetic and non-diabetic subjects (1991) (5)
3.P.81 Immunolocalisation of paraoxonase with clusterin and apolipoprotein A1 in the human artery wall (1997) (4)
PON1 in Other Diseases (2002) (4)
Variability in the measurement of lipoprotein(a) in the British Isles (2009) (4)
A critical review on human serum Paraoxonase-1 in the literature: truths and misconceptions (2020) (4)
IMMUNOHISTOCHEMICAL ANALYSIS OF PARAOXONASES-1, 2, AND 3 IN HUMAN ATHEROMA PLAQUES (2008) (4)
HDL prevents the formation of aldehyde adducts on apo-B during the oxidation of LDL (2000) (4)
Isolation of plasma small-dense low-density lipoprotein using a simple air-driven ultracentrifuge and quantification using immunassay of apolipoprotein B (2004) (3)
9. Role of HDL in preventing atherogenic modification of LDL (1999) (3)
Predominant localization of dihydroxyacetone-phosphate acyltransferase activity in renal peroxisomes of male and female mice. (1985) (2)
Unexpectedly higher diazoxon hydrolysis by serum paraoxonase-1 in coronary heart disease. (2019) (2)
Susceptibility of LDL and HDL from patients with diabetes mellitus to in vitro oxidative modification (1994) (2)
Sexual dimorphism in trans-cypermethrin hydrolysis in the domestic chicken. (1991) (2)
Serum lipoprotein (a) in heterozygotes for familial hypercholesterolaemia (FH) their relatives and controls (1990) (1)
Still life in oxidation hypothesis of atherogenesis (2000) (1)
Concentrations in Men and Women With Familial Hypercholesterolemia , Related and Unrelated , in Unrelated Familial Hypercholesterolemia Probands , in Controls With Normal Serum Lipid Levels , and in Controls With Hypercholesterolemia Not Due to Familial Hypercholesterolemia Variable Norn (2005) (1)
Serum paraoxonase activity in Type 1 and Type 2 diabetes (1994) (1)
Effect of a New Fish Oil Concentrate (OMACOR) on Plasma Lipids and Lipoproteins in Patients with Hypertriglyceridaemia (1995) (1)
Autoantibodies against Oxidised Low Density Lipoprotein in Patients with Coronary Artery Disease (1995) (1)
Effect of oral supplementation with micronutrient antioxidants on trans fatty acid content of lipoproteins in healthy humans. (1996) (1)
Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation (2005) (1)
The Effect of Hypoxia on Growth Factor Gene Expression in Cultured Cells (1995) (1)
Circulating Haemoglobin Levels and the Risk of Atherosclerosis in Asian Indian Populations (2015) (1)
Identification of mutations at the lipoprotein lipase gene locus in subjects with type i hyperlipoproteinemia (1993) (1)
3SY05-6 Paraoxonase: Biochemistry and contribution to atherosclerosis (2003) (1)
Migration Related Differences in Blood Iron Availability Among Resident Compared With Migrant South Asians are Related to Indices of Atherogenesis (2008) (1)
Mouse kidney peroxisomal fatty acyl-CoA oxidase chain length specificity (1986) (1)
Susceptibility of low and high density lipoproteins from subjects with diabetes to in vitro oxidative modification (1995) (1)
Calcium handling in aortic smooth muscle cells of apolipoprotein E-deficient mice transfected with paraoxonase-1 (2005) (0)
Paraoxonase (PON1) & coronary heart disease (2000) (0)
Effect of Antioxidant Supplimentation on the Susceptibility of Low Density Lipoprotein (Ldl) to Oxidation (1994) (0)
Misconceptions about paraoxonase-1 (2021) (0)
Multicentre interlaboratory study of lipoprotein (A) (Lp(A) assay methods (1993) (0)
Serum butyrylcholinesterase activity (BChe) hypertriglyceridaemia and insulin resistance in diabetes mellitus (1993) (0)
Systemic Lupus Erythematosus (2014) (0)
Alterations in the activity of reverse cholesterol transport: a contributing factor to the hyperlipidemia of nephrotic syndrome? (1994) (0)
The effect of insulin, glucagon and oleic acid on the particle size and composition of apolipoprotein B-containing lipoproteins secreted by HEP G2 cells (1995) (0)
4.P.69 Serum platelet activating factor-acetylhydrolase (PAF-AH) activity in diabetes (1997) (0)
3.P.2 The effect of vitamin E on lipoprotein oxidation and cholesteryl ester transfer (1997) (0)
The Heart Protection Study: death knell for the oxidation theory of atherosclerosis? (2002) (0)
Transfer of cholesteryl esters from HDL to VLDL and LDL (CET) is increased in patients with type 2 diabetes mellitus (DM) (1994) (0)
Atherosclerosis Atherosclerosis in Dyslipidemic Obese Mice : LCAT Gene Transfer Decreases Antioxidant Defense Are Associated With Increased Macrophage Homing and Increased Low-Density Lipoprotein Oxidation and Impaired High-Density Lipoprotein (2003) (0)
Vascular risk factors in coronary heart disease (CHD) associated with type 1 diabetes mellitus (1991) (0)
Lipoprotein (a) in the Interstitial Fluid and Serum of Patients with Chronic Renal Failure and Matched Controls (1996) (0)
The role of lipids in the development of the atherosclerotic plaque (2001) (0)
Changes in reverse cholesterol transport (RCT) in nephrotic syndrome (1995) (0)
Raised Creatinine protein in Indian migrant women living in the UK and its relation to CHD risk factors (2001) (0)
Improved glycaemic control and insulin sensitivity during sustained suppression of serum non-esterified fatty acids (NEFA) in type 2 diabetic patients (1995) (0)
Isolation of plasma small-dense LDL using a simple air-driven ultracentrifuge and quantification using immunoassay of apolipoprotein B, (2004) (0)
Fetal and maternal lipoproteins in uncomplicated and diabetic third trimester pregnancy (1996) (0)
Lack of Association of Paraoxonase 1 Promoter Polymorphisms with Gulf War Illness (2015) (0)
Alterations of Reverse Cholesterol Transport in Stable Chronic Renal Impairment (1995) (0)
Multiple formsofsheep serumA-esterase activity associated with thehigh-density lipoprotein (1988) (0)
Hydrolysis of platelet-activating factor by purified HDL-associated paraoxonase (1994) (0)
Corrigendum to "Unexpectedly higher diazoxon hydrolysis by serum paraoxonase-1 in coronary heart disease" [Clinical Biochemistry 65 (2019) 21-23]. (2019) (0)
Hydrolysis of Platelet-Activating Factor by Purified High-Density Lipoprotein Associated Paraoxonase (1995) (0)
Induction of PPARs in the adipose tissue is a key mechanism for the weight loss-induced increase of insulin sensitivity, correction of dyslipidemia, inhibition of atherosclerosis, and improvement of cardiovascular function in obese insulin-resistant mice (2004) (0)
Effect of anti-oxidative enzyme gene-transfer on endothelial cell function of apolipoprotein-E deficient mice (2006) (0)
Intermediate levels of paraoxonase-1 activity are associated to lower intima-media thickness in HIV-infected patients (2008) (0)
Paraoxonase polymorphisms and coronary heart disease. Authors' reply (2004) (0)
182 DETERMINATION OF PARAOXONASE-3 CONCENTRATION IN HUMAN SERUM: METHOD EVALUATION, REFERENCE VALUES AND INFLUENCE OF GENOTYPES IN A POPULATION-BASED STUDY (2011) (0)
Effect on lipoproteins of different progestogens in combination with conjugated oestrogen as hormone replacement therapy (2002) (0)
The secretion of apolipoprotein B containing lipoproteins by hep G2 cells: Effects of glucagon and insulin (1991) (0)
Plasma lipoproteins and markers of cholestasis in patients with psoriasis treated with low-dose cyclosporin (1994) (0)
Serum Lipoprotein (a) Levels in Patients with Familial Hypercholesterolaemia, Their Relatives and Control Populations (Introduced by Mrs Member:- Dr.P.N. Durrington) (1990) (0)
Paraoxonase-1 and Cardiovascular Disease (2008) (0)
Effect of pravastatin on the transfer of cholesteryl esters from HDL to VLDL and LDL (CET) in the fasting and postprandial state in patients with type 2 diabetes mellitus (DM) (1994) (0)
The effects of saturated fatty acids on apolipoprotein B secretion by human hepatoma (Hep G2) cells (1993) (0)
Paraoxonase and arylesterase are the same enzyme in humans (2020) (0)
Protection against accumulation of peroxides in LDL by HDL and its associated enzyme, paraoxonase (1994) (0)
Restricted dietary intake and weight-loss is associated with reversal of hypertriglyceridemia and prevention of atherosclerosis in obese dyslipidemic mice (2003) (0)
W06.169 HDL does not inhibit MCP-1 secretion by endothelial cells, in response to incubation with TNF$alpha; (2004) (0)
Factors Affecting Serum Paraoxonase 1 Activity in Migrant and Resident Gujarati South Asians (2014) (0)
415 MONOCYTE CHEMOATTRACTANT PROTEIN-1 AND PARAOXONASE-1 IN PERIPHERAL ARTERIAL DISEASE: A MODEL OF INTERACTION BETWEEN DEFENSE AGAINST OXIDATIVE STRESS AND INFLAMMATION (2011) (0)
Oral carbocisteine does not lower serum lipoprotein(a) levels. (1991) (0)
Changes in lipoprotein(a) levels measured by six kit methods during growth hormone treatment of growth hormone-deficient adults. (2000) (0)
Serum lipids & apolipoproteins in South Asians living in the UK and their siblings in India (1993) (0)
Paraoxonase: an enzyme of the high density lipoprotein (HDL) with decreased activity in diabetes mellitus and heterozygous familial hypercholesterolaemia (FH) (1990) (0)
Increased transfer of cholesteryl ester (CE) to low density lipoproteins (VLDL & LDL) associated with coronary artery disease (CAD) (1993) (0)
Effect of Antioxidant Supplementatation on the Susceptibility of Low (LDL) and High Density (HDL) Lipoproteins to Oxidation (1995) (0)
Weight-loss changes PPAR expression, reduces atherosclerosis and improves cardiovascular function in obese insulin-resistant mice (2003) (0)
Serum lipoproteins among Indian Gujaratis living in the UK compared to contemporaries in India (2002) (0)
Human Paraoxonase/Arylesterase (Hompona) Gene Polymorphism in Ischaemic Cardiomyopathy (1997) (0)
4P-0955 Inhibition of oxidised-LDL induced endothelial cell MCP-1 production by paraoxonase (PON1) (2003) (0)
Effect of pyrophosphate on dihydroxyacetone-phosphate acyltransferase activity in male albino mouse tissues (1985) (0)
British Medical Journal (1893) (0)
W09.199 Small dense LDL is more common amongst rural Indians compared to migrant contemporaries: Populations susceptible to insulin resistance and metabolic syndrome (2004) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael Ian Mackness?

Michael Ian Mackness is affiliated with the following schools:

University of Rovira i Virgili
KU Leuven
University of Reading
University of Manchester